RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cardiodynamic evaluation of sorfequiline (TBAJ-876) Results from a first-in-human study
Darpo, B., Nedelman, J., Bruning-Barry, R., Hickman, D., Kleiman, R., Lombardi, A., & Hongqi, X. (2026). Cardiodynamic evaluation of sorfequiline (TBAJ-876) Results from a first-in-human study. Antimicrobial Agents and Chemotherapy, 70(3). https://doi.org/10.1128/aac.01273-25
Sorfequiline (TBAJ-876) is a novel diarylquinoline under development for tuberculosis. In a first-in-human, multiple-ascending-dose study, electrocardiogram and pharmacokinetic data were analyzed to assess cardiac repolarization. Placebo-corrected change-from-baseline in QTcF (Delta Delta QTcF) ranged from -11.4 to +2.4 ms without dose dependency. Concentration-QTc modeling showed a shallow, non-significant slope. The predicted mean effect on Delta Delta QTcF at the maximum geometric mean Cmax of sorfequiline's M3 metabolite was -1.1 ms (90% CI -9.5 to 7.4).CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT06058299.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
